Moreover, DLL3 expression dynamically decreases and disappears as tumors evolve and progress due to genetic mutations, epigenetic changes (e.g., mutations in Notch pathway genes or promoter methylation), microsatellite instability, the tumor microenvironment (e.g., immune evasion or hypoxia-induced plasticity), and the stage of the disease [83,84,85]. Here, DLL3 is linked to neoplasm.